Project Grant R44CA295155
Award Date 9/22/25
Completion Date 8/31/27
Dollars Obligated $1.6M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Maryland, USA
Similar Awards
- The federal Project Grant award of $399,129 from the National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), is supporting research at The Johns Hopkins University to develop a combination therapy approach for treating triple-negative breast cancer (TNBC). The project aims to leverage a DDX3 inhibitor, RK-33, to alter the tumor's metabolic environment and enhance the efficacy of immunotherapy. Key activities include evaluating the effects of RK-33 on...
- This $398,728 Project Grant awarded by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) supports the development of a novel homologous recombination (HR) inhibitor, CP-8, to sensitize triple-negative breast cancer (TNBC) cells to DNA-damaging agents. The project aims to examine the synergy of CP-8 with various DNA-damaging therapies, including PARP inhibitors and ionizing radiation, in TNBC cell lines, patient-derived xenograft models, and in vivo...
- This federal Project Grant award of $631,492 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) is focused on identifying nicotinamide N-methyltransferase (NNMT) as a novel target for treating triple-negative breast cancer (TNBC). The key objectives are to: 1) define how NNMT promotes anchorage-independent growth and protects against ferroptosis in TNBC; 2) evaluate the potency, specificity, and mechanism of a newly developed NNMT bisubstrate inhibitor in TNBC; and 3)...
- This federal Project Grant award of $616,071 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research to develop novel adenosine receptor inverse agonists for treating metastatic triple negative breast cancer (TNBC). The primary awardee is the University of Texas Health Science Center at San Antonio, a Hispanic-serving academic medical center with extensive expertise in cancer research and medical services for federal agencies. The University has...
- This federal Project Grant award of $658,561 from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to develop a novel class of MDM2 degraders as a potential therapy for triple-negative breast cancer (TNBC). The award recipient, the University of Tennessee Health Science Center, will perform structure-based optimization of the lead compound CH175 to enhance its binding to the MDM2 ring domain and anti-TNBC potency (Aim 1). Additionally, the project will elucidate the...
- This Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) provides $661,072 to Northwestern University to develop a novel, first-in-class small molecule inhibitor that targets the USP22 oncogene. The goal is to create a therapy with dual immuno-activating and cancer-targeting efficacy to treat triple negative breast cancer. The research, conducted in partnership with startup company Exomira Medicine Inc., aims to advance the therapeutic...
- This federal Project Grant award, provided by the National Cancer Institute (CFDA 93.395 Cancer Treatment Research), supports research to evaluate the preclinical and clinical activity of DNA methyltransferase (DNMT) inhibitors in combination with chemoimmunotherapy for patients with triple-negative breast cancer (TNBC). The $472,447 award, effective December 1, 2024, focuses on identifying biomarkers, such as DNMT3A expression, that can predict response to these targeted therapies. The proposed...
- The National Cancer Institute (NCI) awarded a $215,311 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to the University of Texas Health Science Center at Houston (UTHealth) to conduct preclinical research on the efficacy of GPR56 antibody-drug conjugates (ADCs) and combination therapies for the treatment of triple-negative breast cancer (TNBC). The research aims to develop GPR56 ADCs that can selectively deliver potent cytotoxic drugs to TNBC tumor cells, while sparing...
- This $369,868 federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research to investigate the role of intercellular mitochondrial transfer between nerves and cancer cells, particularly in the context of triple-negative breast cancer metastasis. The project aims to determine how this mitochondrial transfer impacts the metastatic potential of cancer cells and identify key mediators of the process, with the goal of developing potential...
- This $403,485 Project Grant was awarded by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) to The Methodist Hospital Research Institute (HMRI) in Houston, Texas. The grant supports the development of novel platinum-based therapeutics that can produce high levels of reactive oxygen species (ROS) to effectively eradicate triple-negative breast cancer (TNBC) cells and suppress tumor growth. TNBC is an aggressive form of breast cancer with limited...